Imugene Ltd (IMU) - Total Liabilities
Based on the latest financial reports, Imugene Ltd (IMU) has total liabilities worth AU$25.80 Million AUD (≈ $18.26 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IMU strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Imugene Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how Imugene Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Imugene Ltd's balance sheet.
Imugene Ltd Competitors by Total Liabilities
The table below lists competitors of Imugene Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Century Extrusions Limited
NSE:CENTEXT
|
India | Rs933.40 Million |
|
Greenland Acquisition Corp
NASDAQ:GTEC
|
USA | $53.57 Million |
|
Rathbone Brothers PLC
LSE:RAT
|
UK | GBX3.87 Billion |
|
Great Western Mining Corp Plc
IR:8GW
|
Ireland | €770.40K |
|
Bakrie Sumatera Plantations
JK:UNSP
|
Indonesia | Rp8.59 Trillion |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
UK | GBX75.31 Million |
|
Vaswani Industries Limited
NSE:VASWANI
|
India | Rs3.58 Billion |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
USA | $75.94 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down Imugene Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Imugene Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.77 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imugene Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imugene Ltd (1993–2025)
The table below shows the annual total liabilities of Imugene Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$38.56 Million ≈ $27.28 Million |
+16.33% |
| 2024-06-30 | AU$33.14 Million ≈ $23.45 Million |
+345.66% |
| 2023-06-30 | AU$7.44 Million ≈ $5.26 Million |
-16.45% |
| 2022-06-30 | AU$8.90 Million ≈ $6.30 Million |
+31.06% |
| 2021-06-30 | AU$6.79 Million ≈ $4.81 Million |
+25.80% |
| 2020-06-30 | AU$5.40 Million ≈ $3.82 Million |
+54.93% |
| 2019-06-30 | AU$3.48 Million ≈ $2.47 Million |
+142.19% |
| 2018-06-30 | AU$1.44 Million ≈ $1.02 Million |
+12.15% |
| 2017-06-30 | AU$1.28 Million ≈ $907.76K |
-23.60% |
| 2016-06-30 | AU$1.68 Million ≈ $1.19 Million |
+21.45% |
| 2015-06-30 | AU$1.38 Million ≈ $978.36K |
-27.20% |
| 2014-06-30 | AU$1.90 Million ≈ $1.34 Million |
+172.09% |
| 2013-06-30 | AU$698.03K ≈ $493.90K |
+184.94% |
| 2012-06-30 | AU$244.97K ≈ $173.33K |
-48.99% |
| 2011-06-30 | AU$480.28K ≈ $339.83K |
+56.25% |
| 2010-06-30 | AU$307.37K ≈ $217.49K |
-29.62% |
| 2009-06-30 | AU$436.72K ≈ $309.01K |
-11.48% |
| 2008-06-30 | AU$493.37K ≈ $349.09K |
-11.99% |
| 2007-06-30 | AU$560.55K ≈ $396.62K |
-30.46% |
| 2006-06-30 | AU$806.04K ≈ $570.32K |
+95.87% |
| 2005-06-30 | AU$411.52K ≈ $291.18K |
-29.57% |
| 2004-06-30 | AU$584.29K ≈ $413.43K |
-16.62% |
| 2003-06-30 | AU$700.77K ≈ $495.84K |
+1259.15% |
| 2002-06-30 | AU$51.56K ≈ $36.48K |
-98.07% |
| 2001-06-30 | AU$2.67 Million ≈ $1.89 Million |
+195.33% |
| 2000-06-30 | AU$903.09K ≈ $638.99K |
+0.57% |
| 1999-06-30 | AU$898.00K ≈ $635.39K |
-20.95% |
| 1998-06-30 | AU$1.14 Million ≈ $803.79K |
-8.46% |
| 1997-06-30 | AU$1.24 Million ≈ $878.09K |
+10.12% |
| 1996-06-30 | AU$1.13 Million ≈ $797.42K |
-13.64% |
| 1995-06-30 | AU$1.30 Million ≈ $923.37K |
+927.56% |
| 1994-06-30 | AU$127.00K ≈ $89.86K |
-78.36% |
| 1993-06-30 | AU$587.00K ≈ $415.34K |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more